Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Hoffmann-La Roche
Luis Paz-Ares; Hossein Borghaei; Stephen V Liu; Solange Peters; Roy S Herbst; Katarzyna Stencel; Margarita Majem; Mehmet Ali Nahit Şendur; Grzegorz Czyżewicz; Reyes Bernabé Caro; Ki Hyeong Lee; Melissa L Johnson; Nuri Karadurmuş; Christian Grohé; Sofia Baka; Tibor Csőszi; Jin Seok Ahn; Raffaele Califano; Tsung-Ying Yang; Yasemin Kemal; Marcus Ballinger; Vaikunth Cuchelkar; Vilma Graupner; Ya-Chen Lin; Debasis Chakrabarti; Kamalnayan Bhatt; George Cai; Robert Iannone; Martin Reck; IMforte investigators